Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)

被引：1

作者：

Fukuhara, T. ^{[1
]}

Inoue, A. ^{[2
]}

Morita, S. ^{[3
]}

Sugawara, S. ^{[4
]}

Hosomi, Y. ^{[5
]}

Ikeda, S. ^{[6
]}

Gemma, A. ^{[7
]}

Takahashi, K. ^{[8
,9
]}

Fujita, Y. ^{[10
]}

Harada, T. ^{[11
]}

Minato, K. ^{[12
]}

Takamura, K. ^{[13
]}

Kobayashi, K. ^{[14
]}

Nukiwa, T. ^{[15
]}

机构：

[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan

[2] Tohoku Univ, Sch Med, Dept Palliat Med, Sendai, Miyagi, Japan

[3] Kyoto Univ, Dept Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan

[4] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan

[5] Komagome Hosp, Dept Thorac Oncol & Resp Med, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[6] Kanagawa Cardiovasc & Resp Ctr, Div Resp Med, Yokohama, Kanagawa, Japan

[7] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan

[8] Juntendo Univ, Fac Med, Tokyo, Japan

[9] Juntendo Univ, Grad Sch Med, Tokyo, Japan

[10] Asahikawa Med Ctr, Asahikawa, Hokkaido, Japan

[11] Jcho Hokkaido Hosp, Sapporo, Hokkaido, Japan

[12] Gunma Prefectural Canc Ctr, Gunma, Japan

[13] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan

[14] Saitama Med Univ, Hidaka, Japan

[15] Tohoku Univ, Sendai, Miyagi, Japan

来源：

关键词：

EGFR; gefitinib; phase III;

D O I：

10.1016/j.jtho.2018.08.576

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-20

引用

页码：S467 / S467

页数：1